An open-access resource to help catalyze drug discovery for priority viruses of pandemic and endemic concern
To support the global research community in its efforts toward filling the gaps in antiviral R&D that is critical to global health security and the protection of communities worldwide, the INTREPID Alliance has launched the Antiviral Toolbox. This open-access resource is purpose-built to help catalyze the identification and development of small-molecule antivirals, which are indispensable tools for rapid, scalable, and equitable responses to epidemic and pandemic threats.
Click on the elements below to explore the collection of tools housed within the INTREPID Alliance Antiviral Toolbox.
Disclaimer
The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared to respond to future pandemic and endemic threats.
As part of our efforts, the INTREPID Alliance publishes and maintains the Antiviral Toolbox to be a non-promotional resource with the purpose of knowledge-sharing and to support better pandemic preparedness. The Antiviral Toolbox includes the Registry of Antiviral Compound Libraries, a registry of compound libraries designed to facilitate research. These registries are third-party resources and have been developed independently of, and at arm’s length, from INTREPID Alliance and its members. The INTREPID Alliance is not responsible for their content. The INTREPID Alliance also publishes and maintains a centralized list of promising investigational compounds. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. “Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.